The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.

PURPOSE Transurethral bladder tumor resection is one of the most commonly performed procedures by practicing urologists for the diagnosis, staging and treatment of nonmuscle invasive bladder cancer. There is wide variation in the technique and quality of transurethral bladder tumor resection among urologists. This is the first and critically important diagnostic and staging tool in the management of bladder cancer, which is a potentially lethal malignancy and the most costly urological malignancy to manage. In this review we provide an evidence-based rationale for the incorporation of novel technologies for transurethral resection of bladder tumor in the setting of previously set standards. MATERIALS AND METHODS A systematic MEDLINE®/PubMed®, Cochrane Library and Ovid MEDLINE® search was performed using 2 separate search queries. The MEDLINE/PubMed search was performed using the key words "transurethral resection bladder tumor," filtering the search to include studies published within the last 5 years, English language and human species. A second search without filters was performed with the same key words in the Cochrane Library and Ovid MEDLINE. Study eligibility was defined based on patients with nonmuscle invasive bladder cancer, treatment with transurethral bladder tumor resection and with variable comparators based on novel technology used. All study designs were accepted except case reports, animal studies, editorials and review articles with various outcome measures reported including tumor detection, residual tumor detection, disease recurrence/progression and adverse events. RESULTS The literature search ultimately yielded 971 manuscripts for review with 42 meeting inclusion criteria for systematic review. Refinements in technique and surgeon experience are critical for the performance of a thorough, complete, high quality transurethral bladder tumor resection. Recent technological advances including bipolar electrocautery and regional anesthetic techniques may help reduce the complications associated with transurethral bladder tumor resection. Photodynamic diagnosis may help increase the diagnostic accuracy, reduce the recurrence rate and decrease the cost of treating patients with nonmuscle invasive bladder cancer. Repeat transurethral bladder tumor resection and perioperative intravesical chemotherapy remain standard components in select patients with nonmuscle invasive bladder cancer. Appropriate clinical staging and treatment of patients with nonmuscle invasive bladder cancer remain a challenge. CONCLUSIONS Recent advances in transurethral bladder tumor resection should aid its diagnostic accuracy, reduce recurrences, decrease complications and reduce the cost of management of nonmuscle invasive bladder cancer. Urologists should incorporate these evidence-based strategies into current guideline recommendations to improve patient outcomes following transurethral resection of bladder tumor in everyday practice.

[1]  B. Geavlete,et al.  Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. , 2012, Urology.

[2]  M. Pearle,et al.  Best practice policy statement on urologic surgery antimicrobial prophylaxis. , 2008, The Journal of urology.

[3]  Dieter Jocham,et al.  Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. , 2013, European urology.

[4]  Raj Persad,et al.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. , 2011, The Journal of urology.

[5]  Chen Xiangyu,et al.  Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. , 2010, Journal of endourology.

[6]  A. Sabichi,et al.  Clinical model of lifetime cost of treating bladder cancer and associated complications. , 2006, Urology.

[7]  J. Jones,et al.  The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. , 2013, The Canadian journal of urology.

[8]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[9]  Tianxin Lin,et al.  Diagnosis of narrow‐band imaging in non‐muscle‐invasive bladder cancer: A systematic review and meta‐analysis , 2013, International journal of urology : official journal of the Japanese Urological Association.

[10]  K. Shroyer,et al.  Early detection of carcinoma in situ of the bladder: a comparative study of white light cystoscopy, narrow band imaging, 5-ALA fluorescence cystoscopy and 3-dimensional optical coherence tomography. , 2012, The Journal of urology.

[11]  John T. Wei,et al.  Risk factors for adverse outcomes after transurethral resection of bladder tumors , 2006, Cancer.

[12]  S. Mirza,et al.  The Effects of Irrigation Fluid on Core Temperature in Endoscopic Urological Surgery , 2007, Journal of perioperative practice.

[13]  Kerstin Amann,et al.  The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer , 2012, BJU international.

[14]  Dong-rong Yang,et al.  Safety and efficacy of 120W high performance system greenlight laser vaporization for non-muscle-invasive bladder cancer. , 2013, Journal of X-ray science and technology.

[15]  Zhijia Yuan,et al.  On the possibility of time-lapse ultrahigh-resolution optical coherence tomography for bladder cancer grading. , 2009, Journal of biomedical optics.

[16]  A. Seth,et al.  Bipolar energy for transurethral resection of bladder tumours at low‐power settings: initial experience , 2011, BJU international.

[17]  P. Dasgupta,et al.  Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette‐Guérin , 2010, BJU international.

[18]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[19]  M. Babjuk,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[20]  P. Puppo,et al.  Bipolar transurethral resection in saline (TURis): outcome and complication rates after the first 1000 cases. , 2009, Journal of endourology.

[21]  D. Berney,et al.  Handling and reporting of transurethral resection specimens of the bladder in Europe: a web‐based survey by the European Network of Uropathology (ENUP) , 2011, Histopathology.

[22]  K. Grigor,et al.  Good quality white‐light transurethral resection of bladder tumours (GQ‐WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non‐muscle‐invasive bladder cancer: validation across time and place and recommendation for benchmar , 2012, BJU international.

[23]  J. Beyene,et al.  Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. , 2013, European urology.

[24]  M. Valenti,et al.  Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. , 2011, The Lancet. Oncology.

[25]  H. Herr Role of Re-Resection in Non–Muscle-Invasive Bladder Cancer , 2011, TheScientificWorldJournal.

[26]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[27]  D. Goff,et al.  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardi , 2007, Journal of the American Dental Association.

[28]  K. Ogan,et al.  Initial North American experience with the use of the Olympus Button Electrode for vaporization of bladder tumors. , 2012, The Canadian journal of urology.

[29]  H. Grossman,et al.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. , 2010, The Journal of urology.

[30]  Harry Herr Narrow band imaging cystoscopy. , 2011, Urologic oncology.

[31]  Z. Wang,et al.  Subcellular imaging of epithelium with time-lapse optical coherence tomography. , 2007, Journal of biomedical optics.

[32]  M. Rouprêt,et al.  The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. , 2012, The Canadian journal of urology.

[33]  David C. Miller,et al.  Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. , 2012, The Journal of urology.

[34]  R. T. Divrik,et al.  Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. , 2010, European urology.

[35]  N. Wiklund,et al.  Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. , 2010, European urology.

[36]  Karl-Dietrich Sievert,et al.  Virtual Bladder Tumor Transurethral Resection: An Objective Evaluation Tool to Overcome Learning Curves with and without Photodynamic Diagnostics , 2011, Urologia Internationalis.

[37]  H. Grossman,et al.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. , 2007, The Journal of urology.

[38]  M. Soloway,et al.  "Complete transurethral resection of bladder tumor": are the guidelines being followed? , 2010, Urology.

[39]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[40]  W. Meinhardt,et al.  Extravasation of Intravesical Chemotherapy for Non-Muscle-Invasive Bladder Cancer , 2012, Urologia Internationalis.

[41]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[42]  L. Mazzucchelli,et al.  A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. , 2003, The Journal of urology.

[43]  Seongheon Lee,et al.  Ultrasound guided obturator nerve block: a single interfascial injection technique , 2011, Journal of Anesthesia.

[44]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[45]  M. Khorrami,et al.  A comparison between blind and nerve stimulation guided obturator nerve block in transurethral resection of bladder tumor. , 2012, Journal of endourology.

[46]  Maximilian Burger,et al.  Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. , 2012, The Journal of urology.

[47]  A. Mandal,et al.  Efficacy of gabapentin for prevention of postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor. , 2012, Urology.